Invivyd Q2 2026 revenue up 21% to $14.3M; net loss widens to $44.4M; PEMGARDA EUA termination notice

Invivyd, Inc.

Q2 2026 PEMGARDA net product revenue $14.3M, up 21% YoY from $11.8M.
Net loss $44.4M vs $14.7M; EPS -$0.14 vs -$0.12; R&D spend $29.4M vs $9.6M.
Cash $160.1M; runway through DECLARATION data readout and potential VYD2311 launch.
Received 12-month notice of PEMGARDA EUA termination in July 2026; in dialogue with FDA.
DECLARATION enrollment complete, top-line data later Q3 2026; LIBERTY fully dosed, top-line late Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.